Oestradiol
Oestrogen used in feminising HRT and menopausal HRT. Available as tablets, patches, gel and injectable esters.
Medications & hormones
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
Oestradiol
Oestrogen used in feminising HRT and menopausal HRT. Available as tablets, patches, gel and injectable esters.
Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.
Regulatory statement in source: FDA-approved.
Oestradiol is an approved oestrogen medicine with an FDA prescribing label. The label covers menopausal symptoms and other conditions linked to low oestrogen. In February 2026 the FDA approved labelling changes for six menopausal hormone therapy products, removing boxed-warning statements about cardiovascular disease, breast cancer and probable dementia. This is regulator-level information rather than new trial evidence.
Benefits reported in the imported source
- Treats menopausal symptoms.
- Labelled as replacement in female hypoestrogenism due to hypogonadism.
- In February 2026 the FDA removed boxed warnings on heart disease, cancer and dementia from six products.
Risks and limits
- The label still carries boxed warnings on endometrial cancer and cardiovascular risk.
- The 2026 change is a regulatory labelling decision, not new trial evidence.
Source bottom line: Oestradiol is an FDA-approved oestrogen for menopausal and low-oestrogen conditions, with boxed warnings.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
women with moderate to severe vasomotor symptoms of the menopause, per the US Depo-Estradiol label
- Reported regimen
- 1 to 5 mg estradiol cypionate injected intramuscularly every 3 to 4 weeks
- Duration
- short-term cyclic use, with attempts to stop or taper at 3- to 6-month intervals
- Reported outcome
- The label lists this as the approved regimen for menopausal vasomotor symptoms and carries boxed warnings on endometrial cancer and cardiovascular risk.
- Source
- Depo-Estradiol (estradiol cypionate injection) FDA Label
Claim provenance
evidence.json#/catalog:hormone:estradiol/protocols/0
women with hypoestrogenism due to hypogonadism, per the US Depo-Estradiol label
- Reported regimen
- 1.5 to 2 mg estradiol cypionate injected intramuscularly at monthly intervals
- Duration
- ongoing, per the label, with reassessment at 3- to 6-month intervals
- Reported outcome
- The label lists this as the approved regimen for female hypoestrogenism due to hypogonadism.
- Source
- Depo-Estradiol (estradiol cypionate injection) FDA Label
Claim provenance
evidence.json#/catalog:hormone:estradiol/protocols/1
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Unverified imported account — Estrogen Patches for hormone replacement therapy
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unit interpretation unverified. The imported patch account mixes labelled delivery-rate units, patch counts and a weekly total. The stated weekly arithmetic is not verified and must not be used to calculate an administered dose. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A community-focused HRT platform documents that most estradiol patch users receive 100 mcg patches applied two at a time, lasting 3-4 days, which totals approximately 400 mcg per week as an average weekly dosage.
Pharmacokinetic context
No half-life recorded in this source snapshot. No value has been inferred.
Source references
- Depo-Estradiol (estradiol cypionate injection) FDA Label
- FDA approves labelling changes to menopausal hormone therapy products (2025)
- EMA: product information
Snapshot provenance
Source ID: catalog:hormone:estradiol. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.
Related entries and components
None listed.